Literature DB >> 492836

Comparative pharmacokinetics of amoxicillin and ampicillin in infants and children.

C M Ginsburg, G H McCracken, M L Thomas, J Clahsen.   

Abstract

The pharmacokinetics of amoxicillin and ampicillin were studied in 24 infants and children. Mean peak serum concentrations of 5.4 micrograms/ml in fasting and 3.2 micrograms/ml in nonfasting patients were observed after 15 mg/kg amoxicillin doses. Area under the curve values and serum half-life values were similar in fasting and nonfasting patients. The pharmacokinetics of amoxicillin (15 mg/kg) were compared to those of ampicillin (25 mg/kg). Peak serum concentrations, area under the curve values and half-life times were comparable for the two drugs. Amoxicillin (25 mg/kg) and ampicillin (25 mg/kg) were compared in cross-over fashion in 11 children. Serum concentrations of amoxicillin were consistently larger than those of ampicillin; the differences were of borderline significance at one and two hours and statistically significant at four and six hours after the dosage. The bioavailability of amoxicillin was twice that of ampicillin. Amoxicillin was detected in approximately half of the saliva samples studied. Although the salivary concentrations in many children exceeded the inhibitory level for most pneumococci and group A streptococci and for many non-beta lactamase-producing Haemophilus influenzae type b strains, the clinical relevance of these observations is unknown.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 492836

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  16 in total

Review 1.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Pharmacokinetic studies in infants using minimal-risk study designs.

Authors:  Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Curr Clin Pharmacol       Date:  2014

3.  Pharmacokinetic study of a paediatric formulation of amoxycillin and clavulanic acid in children.

Authors:  C H van Niekerk; J van den Ende; H K Hundt; E A Louw
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Interactions affecting drug absorption.

Authors:  P G Welling
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

5.  The "new" ampicillins: who needs them? Committee on Infectious Diseases and Immunization, Canadian Paediatric Society.

Authors: 
Journal:  Can Med Assoc J       Date:  1984-11-15       Impact factor: 8.262

6.  A comparison of the pharmacokinetics of bacampicillin, ampicillin, amoxicillin, and cyclacillin: oral administration in infants and children.

Authors:  G M McCracken
Journal:  Bull N Y Acad Med       Date:  1983-06

7.  Decreased Streptococcus pneumoniae susceptibility to oral antibiotics among children in rural Vietnam: a community study.

Authors:  Nguyen Quynh Hoa; Nguyen V Trung; Mattias Larsson; Bo Eriksson; Ho D Phuc; Nguyen Tk Chuc; Cecilia Stalsby Lundborg
Journal:  BMC Infect Dis       Date:  2010-03-31       Impact factor: 3.090

8.  Pharmacokinetics of potassium clavulanate in combination with amoxicillin in pediatric patients.

Authors:  J D Nelson; H Kusmiesz; S Shelton
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

Review 9.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

10.  On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food.

Authors:  Marina Statelova; Konstantinos Goumas; Nikoletta Fotaki; René Holm; Mira Symillides; Christos Reppas; Maria Vertzoni
Journal:  AAPS J       Date:  2019-12-02       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.